Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial - Scorecard - MDSpire

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial

  • By

  • Hideaki Bando

  • Jun Watanabe

  • Yusuke Takahashi

  • Masahito Kotaka

  • Nobuhisa Matsuhashi

  • Eiji Oki

  • Yoshito Komatsu

  • Manabu Shiozawa

  • Keiji Hirata

  • Yuji Miyamoto

  • Masanobu Takahashi

  • Kentaro Yamazaki

  • Dai Manaka

  • Akiyoshi Kanazawa

  • Yi-Hsin Liang

  • Kun-Huei Yeh

  • Yuko Watsuji

  • Yuko Yamamoto

  • Makoto Fukui

  • Shruti Sharma

  • Vasily N. Aushev

  • Adham Jurdi

  • Matthew Rabinowitz

  • Minetta C. Liu

  • Alexey Aleshin

  • Ichiro Takemasa

  • Daisuke Kotani

  • Akihiro Sato

  • Toshihiro Misumi

  • Yoshiaki Nakamura

  • Qian Shi

  • Hiroya Taniguchi

  • Takayuki Yoshino

  • Takeshi Kato

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Adjuvant Chemotherapy Following Resection in ctDNA-Positive Colorectal Cancer Patients: Results from a Phase 3 Randomized Trial

At a Glance

CategoryDetail
Condition
Key MechanismsctDNA as a biomarker for MRD detection and treatment decision-making (source needed).
Target Population
Care Setting

Key Highlights

  • Remove unsupported claims about FTD/TPI efficacy.

Guideline-Based Recommendations

Diagnosis

    Management

    • A
    • d
    • m
    • i
    • n
    • i
    • s
    • t
    • e
    • r
    • A
    • C
    • T
    • f
    • o
    • r
    • h
    • i
    • g
    • h
    • -
    • r
    • i
    • s
    • k
    • s
    • t
    • a
    • g
    • e
    • I
    • I
    • a
    • n
    • d
    • a
    • l
    • l
    • s
    • t
    • a
    • g
    • e
    • I
    • I
    • I
    • C
    • R
    • C
    • p
    • a
    • t
    • i
    • e
    • n
    • t
    • s
    • (
    • s
    • o
    • u
    • r
    • c
    • e
    • n
    • e
    • e
    • d
    • e
    • d
    • )
    • .

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with resectable clinical stage 0–IV CRC, specifically ctDNA positive post-surgery.

        FTD/TPI may improve outcomes in ctDNA-positive patients post-surgery.

        Clinical Best Practices

        • Remove unsupported recommendation regarding ctDNA-guided treatment strategies.

        Related Resources & Content

        Original Source(s)

        Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial

        • by Hideaki Bando, Jun Watanabe, Yusuke Takahashi, Masahito Kotaka, Nobuhisa Matsuhashi, Eiji Oki, Yoshito Komatsu, Manabu Shiozawa, Keiji Hirata, Yuji Miyamoto, Masanobu Takahashi, Kentaro Yamazaki, Dai Manaka, Akiyoshi Kanazawa, Yi-Hsin Liang, Kun-Huei Yeh, Yuko Watsuji, Yuko Yamamoto, Makoto Fukui, Shruti Sharma, Vasily N. Aushev, Adham Jurdi, Matthew Rabinowitz, Minetta C. Liu, Alexey Aleshin, Ichiro Takemasa, Daisuke Kotani, Akihiro Sato, Toshihiro Misumi, Yoshiaki Nakamura, Qian Shi, Hiroya Taniguchi, Takayuki Yoshino, Takeshi Kato

        • June 8, 2026

        Related Content

        Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia

        Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy

        Comparative analysis of anal sphincter-preserving surgical techniques in ultra-low rectal cancer